NEOVACS SECURES FINANCING FROM THE ANR - THE FRENCH NATIONAL RESEARCH AGENCY - TO DEVELOP THE IL-4/IL-13 KINOID AS AN ALLERGY...
08 Janvier 2019 - 07:30AM
PRESS RELEASE
· PRESS RELEASE · PRESS RELEASE
NEOVACS SECURES
FINANCING FROM THE ANR
- THE FRENCH NATIONAL RESEARCH AGENCY
-
TO DEVELOP THE IL-4/IL-13 KINOID AS AN ALLERGY
TREATMENT
Paris and Boston,
January 8, 2019 - 7:30 CET - Neovacs (Euronext
Paris Growth Paris: ALNEV), leader in active immunotherapy for
the treatment of auto-immune diseases, announces that its
AllergyVACS project has been selected to receive funding from the
French National Research Agency (ANR) following the latter's
AAPG 2018 internal assessment process.
The AllergyVACS project aims to
formulate Kinoid vaccines that neutralize the IL-4 and IL-13
cytokines, providing long-term protection against allergies.
Neovacs issued a press release in December 2018 and filed a patent
with the relevant authorities after obtaining preclinical proof of
concept in an asthma model.
The agreement between Neovacs and
the ANR provides €702,000 in funding, which will be split between
the project's two academic partners, namely INSERM (French National
Institute of Health and Medical Research) and the Immunology and
Allergy department of the Institut Pasteur, led by Dr. Pierre
Bruhns and Dr. Laurent Reber. The grant will help to cover the
cost of the next preclinical stages in the AllergyVACS program.
"The ANR's
support is an endorsement of Neovacs' highly innovative therapeutic
vaccine technology, which aims to provide a novel treatment for
allergies-an increasingly prevalent global public health
challenge", commented Miguel Sieler, Neovacs' Chief Executive
Officer.
The development of this new Kinoid
is underpinned by the same technology platform as the
IFNalpha Kinoid, which was recently boosted by the results of
its Phase IIb trials in lupus.
About
Neovacs
Listed on Euronext Growth since 2010, Neovacs is today a leading
biotechnology company focused on an active immunotherapy technology
platform (Kinoids) with applications in autoimmune and/or
inflammatory diseases. On the basis of the company's proprietary
technology for inducing a polyclonal immune response (covered by
four patent families that potentially run until 2032) Neovacs is
focusing its clinical development efforts on IFNalpha Kinoid,
an immunotherapy being developed for the indication of lupus,
dermatomyositis and also in preclinical trial for Type 1 diabetes.
Neovacs is also conducting preclinical development works on other
therapeutic vaccines in the fields of auto-immune diseases,
oncology and allergies. The goal of the Kinoid approach is to
enable patients to have access to safe treatments with efficacy
that is sustained in these life-long diseases. www.neovacs.fr
Contacts
NEOVACS -
Corporate Communication & Investor Relations
Charlène Masson
+33 1 53 10 93 00
cmasson@neovacs.com
NEWCAP-
Media
Annie-Florence Loyer
+33 1 44 71 00 12 / + 33 6 88 20 35 59
afloyer@newcap.fr
Léa Jacquin
+33 1 44 71 20 41 / +33 6 58 14 84 66
ljacquin@newcap.fr
Press release
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: NEOVACS via Globenewswire
Neovacs (EU:ALNEV)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Neovacs (EU:ALNEV)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024